The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

Alpha-1 is a microcosm of the rare disease world. The challenges we face, late diagnoses, inconsistent care, and unaffordable ...

A fourth revolution in cancer care is taking shape, one that steps away from the current well-trodden path. This revolution ...

The Health and Human Services (HHS) Secretary named eight hand-picked members of the Advisory Committee on Immunisation ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an ...

As major pharmacy chains like Walgreens continue to close hundreds of stores nationwide, pharmacy deserts are increasing ...

At ASCO 2025, ImmunityBio’s chief medical officer, Dr Sandeep Reddy, spoke with pharmaphorum about the importance of FDA Expanded Access authorisation for its Cancer BioShield platform, anchored by ...

9 June 2025: The PM (Pharmaceutical Marketing) Society is delighted to announce a new partnership with the CIM (Chartered Institute of Marketing) to build capability and excellence in marketing in the ...

Type of data available on UK Pharmascan registration, with a breakdown on whether the live record is for a new indication, ...

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of ...